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Abstract
Background
Although mobilization of hematopoietic stem cells and hematopoietic progenitor cells can be achieved with combination of G-CSF and plerixafor (AMD3100), improving approaches for hematopoietic progenitor cell mobilization are clinically important.
Design and Methods
Heparan sulfate proteoglycans are ubiquitous macromolecules associated with the extracellular matrix that regulates biology of hematopoietic stem cells. Here, we studied the effects of a new family of synthetic oligosaccharides mimicking heparan sulfate on hematopoietic stem cell mobilization. These oligosaccharides were administered intravenously alone or in combination with G-CSF and/or AMD3100 in mice. Mobilized hematopoietic cells were counted and phenotyped at different times and ability of mobilized hematopoietic stem cells to reconstitute long-term hematopoiesis was determined by competitive transplantation into syngenic lethally irradiated mice followed by secondary transplantation. 
Results
Mimetics
Introduction
In adult mammals, a contingent of hematopoietic stem cells (HSCs) present in the bone marrow (BM) gives rise to all mature blood cells through the process of hematopoiesis. These cells are present in very small number in BM and require a particular microenvironment to self-renew and/or to give hematopoietic progenitor cells (HPCs). HSCs are located within specialized niches in the BM [1, 2] consisting of hematopoietic and non-hematopoietic cells and the extracellular matrix (ECM) [3] [4] [5] . This microenvironment drives the fate of HSCs by regulating their proliferation, quiescence and/or determination. Although tightly bound to their niches, HSCs can traffic between bone marrow, peripheral blood and secondary organs in response to endogenous or exogenous stresses, a process called mobilization [6] [7] [8] . Conversely, injection of HSCs into lethally irradiated mice results in migration of HSCs from bloodstream to bone marrow followed by homing and engraftment of these cells in the bone marrow. Cell mobilization from the bone marrow to the peripheral blood (PB) has become an important source of hematopoietic stem and progenitor cells (HSPCs) for hematopoietic stem cell transplantation and the optimal method to mobilize HSPCs remains a field of intense research. Three cross-talking pathways mainly regulate mobilization: the first one involves the chemokine receptor CXCR4
and its ligand SDF-1, the second one involves the α4β1 integrin VLA-4 and its ligand VCAM-1 and the third one involves the interactions between HSCs and various ECM components [9, 10] . Granulocyte-Colony Stimulating Factor (G-CSF), the most common therapeutic agent used to mobilize HSCs and HPCs for transplantation in patients after myeloablative treatment [11, 12] , essentially acts through disruption of SDF-1/CXCR4 axis [12] [13] [14] . However, broad inter-individual variability of mobilization efficacy exists and poor HSPCs mobilization in response to G-CSF is observed in 
Design and Methods
Animals
Mouse strain C57BL/6J was obtained from the "Centre de Recherche et d'Elevage Janvier" (France). Animal care was in accordance with French Government procedures (Services Vétérinaires de la Santé et de la Production Animale, Ministère de l'Agriculture, France).
Mobilization of White Blood Cells (WBCs) by G-CSF, AMD3100, EP80006 and EP80031
EP80006 and EP80031 are respectively synthetic hexa-and octa-saccharides ( Figure   1A ) produced by Endotis Pharma. These oligosaccharides were shown to be endotoxin free (Lonza, Verviers, Belgium). G-CSF (Neupogen, AMGEN), AMD3100 (SigmaAldrich), EP80006 or EP80031 (Endotis Pharma, EP) were supplied as isotonic aqueous solutions. G-CSF was administered subcutaneously twice a day for two or four days and the morning of the third or fifth day at the dose of 2.5 µg for each mouse. AMD3100 was administered subcutaneously with a unique injection at the dose of 5 mg/Kg. EP80031 and EP80006 were administered intravenously with a unique injection at the dose of 15 mg/Kg. Blood samples were collected 30 min, 1, 3 and 5 hours after the last injection of G-CSF or the injection of AMD3100 and/or EP products. Peripheral blood leukocytes (PBL) were counted with an automatic hematology analyzer (Abacus Junior Vet; Diatron, Vienna, Austria) and then labeled with a combination of fluorescent antibodies to characterize mobilized HSPCs. Four kinds of compounds combinations were used to study WBC mobilization: (i) AMD3100 + EP80031, (ii) G-CSF + EP80031, (iii) G-CSF + AMD3100 and (iv) G-CSF + AMD3100 + EP80031. PBL samples were collected 30 minutes, 1, 3 and 5 hours after the last injection of AMD3100 or EP80031. 
Data analysis and statistics
Values are presented as the mean, median or cell number ± SEM (Standard Error of the Mean). Statistical comparisons between groups were done using the Student's ttest, p < 0.05 (*) and p < 0.001 (**).
Results
A synthetic octosaccharide can mobilize hematopoietic stem cells (HSCs)
New synthetic oligosaccharides, hexa-(EP80006) and octo-(EP80031) saccharides, mimicking the structure of heparan sulfate [26] were designed to efficiently compete with endogenous heparan sulfate. These two oligosaccharides differ in the number of sugar repetitions ( Figure 1A ) and possess an unnatural substituent group that increases their affinity and/or their selectivity (data not shown). To characterize the ability of these compounds to mobilize hematopoietic cells, EP80006 and EP80031
(15 mg/kg) were intravenously injected into C57BL/6 mice and peripheral white blood 
EP80031 has the same efficiency to mobilize HSPCs than G-CSF or AMD3100
As injection of EP80031 resulted in a rapid and transient HSPC mobilization, its effects were compared to those of AMD3100, a compound known to rapidly mobilize The clonogenic potential of mobilized PB HSPCs was evaluated after G-CSF, AMD3100 or EP80031 injections. Blood cells from mice treated with G-CSF, AMD3100 or EP80031 were cultured in semi-solid methylcellulose and colony forming units (CFUs) were quantitatively and qualitatively scored after 7 days of culture. The total number of CFUs was similar after EP80031, AMD3100 or G-CSF treatments (EP80031: 590 ± 50 vs. AMD3100: 690 ± 60 and G-CSF: 630 ± 78 CFU/mL) ( Figure 2C , left panel). However, the colonies obtained were qualitatively different: CFU-G was the predominant colony type observed after AMD3100 injection (310±22 CFU/mL), CFU-GM was the most abundant colony type found after G-CSF treatment (243 ± 24 CFU/mL), whereas, after injection of EP80031, CFU-G, CFU-GM and CFU-GEMM showed similar numbers (180 ± 21, 146 ± 38 and 150 ± 12 CFU/mL, respectively) ( Figure 2C, left panel) . Finally, G-CSF and EP80031
treatments resulted in higher concentrations of immature myeloid colonies (CFUGEMMs) when compared to AMD3100 injection (G-CSF: 115±15 CFU/mL; EP80031:
151±11 CFU/mL and AMD3100: 105±16 CFU/mL) ( Figure 2C , left panel).
Taken together, these results show that the EP80031 compound has the same capacity to mobilize hematopoietic cells enriched in HSCs as G-CSF and AMD3100
but with different kinetics. In addition, EP80031 treatment results in increased number of the multi-potential CFU-GEMMs when compared to AMD3100 and G-CSF treatments, suggesting a better ability to mobilize immature hematopoietic cells.
EP80031 can act in synergy with the G-CSF + AMD3100 combination to mobilize HSPCs
To study if EP80031 acted on pathways already activated by G-CSF-and/or AMD3100 to mediate the mobilization of WBCs and of HSPCs, mobilization mediated by combinations of EP80031 with G-CSF, with AMD3100 or with G-CSF + AMD3100
were compared to mobilization induced by G-CSF + AMD3100. Addition of EP80031 resulted in a higher number of mobilized WBCs compared to control and combination of G-CSF and AMD3100 one hour after AMD3100 or EP80031 injection (G-CSF + These results show that adding EP80031 to the G-CSF + AMD3100 combination strongly increased the number of hematopoietic progenitors without affecting their clonogenic capacity and indicates that EP80031 most probably enhances the effects of G-CSF and/or AMD3100.
HSCs mobilized by the G-CSF + AMD3100 + EP80031 combination reconstitute long-term hematopoiesis
We studied if the three-fold increased number of mobilized KLS had the capacity to heparan-sulfate is linked to the length of the polysaccharide chain and its pattern of sulfatation [43] [44] [45] .
After EP80031 treatment, a rapid increased number of KLS cells was found in PB and the kinetics of KLS mobilization correlated with an increase of serum SDF-1 and VEGF concentrations. This phenomenon strengthened (i) the link between plasma SDF-1 levels and HSPCs egress from the bone marrow, a capacity associated with the metalloproteinase MMP-9 activation [46, 47] , and (ii) the involvement of the VEGF pathway in mobilization and recruitment of HSCs [48] . It was also recently shown that rapid mobilization of HSPCs by AMD3100 might be accounted for by a CXCR4-dependent SDF-1 release into the circulation of mice [47] . When compared to AMD3100, EP80031 had a better potential to increase PB leukocyte concentration and a similar ability to mobilize HSCs. The difference in the kinetics of WBC mobilization by AMD3100 and EP80031 might be explained, in part, by a different way of administration (intravenous for the EP80031 and subcutaneous for the AMD3100) but more likely by the activation of different retention/egress pathways.
EP80031 as AMD3100 might act on CXCR4/SDF1 axis to mobilize hematopoietic cells as we observed an increased plasma level of SDF1 after EP80031 injection.
However, heparan sulfates also regulate the sphingosine 1-phosphate (S1P) signaling pathway [49] that controls recirculation of lymphocytes [50] and egress
HSPCs from the bone marrow [51] , suggesting that EP80031 might also act on this pathway to enhance hematopoietic cell mobilization.
A synergic and potentializing effect on KLS cell mobilization was shown when EP80031 was added to G-CSF or/and AMD3100 treatments. As the number of WBCs in PB after G-CSF + AMD3100 + EP80031 treatment was only increased 1.5 time compared to G-CSF + AMD3100 treatment whereas the number of KLS cells 
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